Atopic Dermatitis : New Developments - 21/11/18

Doi : 10.1016/j.det.2018.07.003

Ayan Kusari, MA ^a,^b,^c, Allison M. Han, BA ^a,^b,^c, David Schairer, MD ^a,^b,^c, Lawrence F. Eichenfield, MD ^a,^b,^c,^⁎
^a Division of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, 8010 Frost Street, Suite 602, San Diego, CA 92123, USA
^b Department of Dermatology, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
^c Department of Pediatrics, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA

^∗Corresponding author. Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, 8010 Frost Street, Suite 602, San Diego, CA 92123, USA.Division of Pediatric and Adolescent DermatologyChildren's Hospital8010 Frost StreetSuite 602San DiegoCA92123USA

Résumé

Herein we review recent developments in our understanding and treatment of atopic dermatitis. Key insights from the recent literature are summarized, from findings on the pathogenesis of this multifactorial disease to a new and more nuanced understanding of its natural history. Therapeutic advances and new data on comorbidities are also discussed.

Le texte complet de cet article est disponible en PDF.

Keywords : Atopic dermatitis, Eczema, Pathogenesis, Treatment, Comorbidities, Prevention

Plan

Disclosure Statement: Mr A. Kusari, Ms A.M. Han, and Dr L.F. Eichenfield all consent to publication of this article in its current form. Mr A. Kusari and Ms A.M. Han report no conflicts of interest or financial disclosures related to this case. Dr L.F. Eichenfield reports no financial relationships relevant to the article. Dr L.F. Eichenfield has been a principal investigator for, Galderma Laboratories, LP, Medimetriks, and Ortho Dermatology and he has received compensation for his work as a consultant for Anacor/Pfizer, Dermavant, Dermira, Leo, Lilly, Novan, Novartis, Regeneron/Sanofi and Ortho Dermatology. This project was partially supported by the National Institutes of Health, Grant TL1TR001443 CTSA funding, and the Rady Children's Hospital/UCSD Eczema and Inflammatory Skin Disease Center.